Wang C, et al. - Researchers compared clinical outcomes of up-front radiotherapy (RT) and tyrosine kinase inhibitor (TKI) with TKI alone for non-small cell lung cancer (NSCLC) patients with brain metastases (BM) and EGFR mutations by analyzing relevant database from Embase, Pubmed, Web of Science, Medline, the Cochrane Library and important oncology meetings. Seven studies with 1086 patients were found eligible for meta-analyses. Findings demonstrated that a higher intracranial progression-free survival and overall survival were provided by up-front RT and TKI, especially in patients with limited number of brain metastases, as compared with TKI alone.